Blood Chemistry and ECG Screening for Average-Risk Adults Aged 50-75
For an average-risk adult aged 50-75 without known cardiovascular disease or diabetes, you should obtain a standard fasting lipid profile (total cholesterol, LDL, HDL, triglycerides) and calculate their 10-year ASCVD risk, but a resting ECG is optional and provides minimal additional benefit for risk stratification.
Blood Chemistry Testing
Essential Tests
Lipid screening is the cornerstone of cardiovascular risk assessment in this population 1, 2, 3:
- Total cholesterol and HDL cholesterol (can be measured fasting or non-fasting)
- LDL cholesterol (requires fasting sample)
- Triglycerides (requires fasting)
- Non-HDL cholesterol (calculated from the profile)
The 2019 ACC/AHA guidelines strongly recommend routine assessment of traditional cardiovascular risk factors and calculation of 10-year ASCVD risk using the pooled cohort equations for all adults 40-75 years of age 3. This lipid panel should be repeated every 3-5 years if the Framingham Risk Score is <5%, or annually if ≥5% 4.
Additional Chemistry Tests to Consider
C-reactive protein (CRP) measurement can be useful in specific circumstances 1:
- For men ≥50 or women ≥60 years with LDL <130 mg/dL
- Not on lipid-lowering therapy
- Without diabetes, chronic kidney disease, or severe inflammatory conditions
- To help decide about statin therapy initiation
Hemoglobin A1C may be reasonable for cardiovascular risk assessment in asymptomatic adults without diagnosed diabetes 1, though this is a weaker recommendation (Class IIb).
Fasting glucose should be obtained to screen for diabetes/prediabetes, as diabetes fundamentally changes risk stratification 5, 3.
Serum creatinine with eGFR calculation is recommended to assess kidney function, as chronic kidney disease is a significant cardiovascular risk factor 6, 7.
Tests NOT Recommended
Advanced lipid testing (lipoproteins, apolipoproteins, particle size/density) beyond a standard fasting lipid profile is not recommended for routine cardiovascular risk assessment 1.
Electrocardiogram (ECG)
The Evidence on Resting ECG
A resting ECG provides minimal benefit for risk stratification in average-risk, asymptomatic adults without hypertension or diabetes 1. The 2010 ACC/AHA guidelines give this only a Class IIb recommendation (may be considered), with Level of Evidence C 1.
Why ECG Has Limited Value
Recent research demonstrates that:
- When SCORE risk factors (age, sex, smoking, blood pressure, cholesterol) are already available, adding ECG abnormalities provides minimal improvement in risk classification 8
- The net reclassification improvement is small (around 1% or less) 8
- ECG screening in asymptomatic primary care patients cannot be recommended for routine use, as harms (unnecessary testing, emotional distress, increased costs) are poorly documented and benefits uncertain 9
When ECG May Be Reasonable
Exercise ECG testing may be considered for 1, 10:
- Intermediate-risk asymptomatic adults (7.5-20% 10-year ASCVD risk)
- Sedentary adults considering vigorous exercise programs
- Men >40-45 years or women >50-55 years with ≥1 coronary risk factor who desire vigorous competitive activities
- Focus on non-ECG markers like exercise capacity, not just ST-segment changes
Resting ECG becomes more valuable in older adults (≥65 years), where major and minor ECG abnormalities are associated with increased CHD events 11, though even here the incremental benefit over traditional risk factors is modest.
Clinical Algorithm
For your average-risk 50-75 year old patient:
- Obtain fasting lipid panel (total cholesterol, LDL, HDL, triglycerides)
- Calculate 10-year ASCVD risk using pooled cohort equations
- Obtain fasting glucose and serum creatinine with eGFR
- Consider CRP if borderline/intermediate risk and statin decision uncertain
- Skip routine resting ECG unless:
- Patient has hypertension or diabetes (changes risk category)
- Intermediate risk (≥7.5% 10-year risk) and considering exercise program
- Symptoms develop
Important Caveats
- Age matters: These recommendations apply to adults 40-75 years. For those ≥76 years, evidence for statin initiation is insufficient 2
- Risk calculation limitations: The pooled cohort equations may overestimate risk in contemporary populations 2, 3
- Confirm abnormal results: Repeat lipid measurements on a separate occasion and average the results before making treatment decisions 12
- Don't rely on computer-interpreted ECGs alone: If you do obtain an ECG, it must be interpreted by a qualified physician 13
The key is using the lipid panel to calculate absolute cardiovascular risk, which then guides intensity of preventive interventions—not ordering tests indiscriminately.